Q-omics provides the consensus-scored AARD profile across patient tissues and cancer cell-line models. AARD expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, AARD is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, AARD RNA expression shows 14,129 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KICH, and TGCT as cancer lineages where AARD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AARD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AARD survival associations across molecular data types. AARD RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AARD RNA expression–survival associations across cancer types. High AARD expression shows unfavorable associations in UCEC, BLCA and GBM, but favorable associations in HNSC, ESCA and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for AARD RNA expression.
This table summarizes AARD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for AARD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AARD shows lower tumor expression in KICH, BLCA, LUAD, COAD and KIRC and higher tumor expression in BRCA. The KICH box plot shows higher AARD RNA expression in normal versus tumor tissue (log2 FC = −1.351, t-test p < 0.001).
This table shows molecular features associated with AARD in patient tissues and cancer cell lines. In patient samples, AARD shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, AARD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
